Co-Investigators - Prof Ian Jacobs; Prof Mahesh Parmar, Dr Steve Skates, Prof Alistair McQuire; Prof Stuart Campbell; Prof Dame Lesley Fallowfield
The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) trial involving 202,000 women has shown that it is possible to detect ovarian cancer with high sensitivity, specificity, positive predictive value, acceptability and compliance using a multimodal screening strategy which combines serum CA125 interpreted using the risk of ovarian cancer algorithm, transvaginal ultrasound and clinical assessment.
There was a significant increase in early stage cancers detected in the multimodal arm compared to women who had no screening. No other screening strategy has achieved this.
As with other forms of cancer screening, there was unnecessary surgery but the surgical false positive rate with multimodal screening was lower than with any other prospectively evaluated screening strategy for ovarian cancer. One in four women who underwent surgery had ovarian cancer.
While the multimodal screening strategy was associated with a reduction in ovarian cancer deaths on follow up to 14 years, the latter was not definitive and needs to be confirmed on follow up which is underway. The final results of this follow-up are expected in January 2021.
There is therefore currently insufficient evidence to recommend ovarian cancer screening in the general population.
ISCRTN number: 22488978
UKCRN ID: 786
North West Multicentre Research Ethics Committee Reference 00/8/34
Initial approval: 21st June 2000
Extended follow up till 31st December 2024: 4th Sept 2014
Detailed protocol of long term follow-up: 24th Jan 2017